{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "VRCI.L",
  "generated_at": "2026-02-10T20:06:20.517503Z",
  "top_card": {
    "ticker": "VRCI.L",
    "company_name": "Verici Dx plc",
    "sector": "Healthcare",
    "market_cap_gbp": 10442419,
    "days_active": 0,
    "apex_score_100": 42,
    "confidence_score_100": 50,
    "ai_final_score_25": 13,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 42/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Verici Dx plc",
      "sector": "Healthcare",
      "industry": "Diagnostics & Research",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 10442419,
      "current_close_price": 0.69
    },
    "basics": {
      "ticker": "VRCI.L",
      "current_price": 0.69,
      "ath": 94.95,
      "atl": 0.466,
      "ath_date": "2021-02-08",
      "atl_date": "2025-08-06",
      "week_52_high": 3.75,
      "week_52_low": 0.466,
      "week_52_high_date": "2025-03-06",
      "week_52_low_date": "2025-08-06",
      "drawdown_from_ath_pct": 99.27,
      "data_start": "2020-11-03",
      "data_end": "2026-02-10",
      "total_bars": 1330
    },
    "latest_signal": {
      "date": "2026-02-10",
      "scan_date": "2026-02-10",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 0.68,
      "drawdown_pct": 81.87,
      "ai_score": 11.0,
      "rsi": 0.0,
      "cycle_position": 0.0912,
      "holding_period_days": 0,
      "current_pnl_pct": 1.47,
      "rally_state": "peaked",
      "distance_from_high_pct": 0.0,
      "Rally_Count": 0,
      "days_since_last_high": 0,
      "last_high_date": "2026-02-10",
      "lock_in_reached": false,
      "lock_in_date": NaN,
      "best_rally_pct": 0.0
    },
    "best_historical_signal": {
      "signal_date": "2023-03-20",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "entry_price": 4.75,
      "peak_price": 19.0,
      "peak_date": "2023-05-04",
      "rally_pct": 300.0,
      "days_to_peak": 45,
      "ai_score": 10.0
    },
    "all_historical_signals": [
      {
        "signal_id": "VRCI.L_2022-06-22",
        "signal_date": "2022-06-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 16.0,
        "current_price": 0.7025,
        "current_return_pct": -95.61,
        "best_rally_pct": 43.75,
        "best_rally_date": "2022-06-30",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -96.95,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1314,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-03",
        "signal_date": "2022-10-03",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1211,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-04",
        "signal_date": "2022-10-04",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 14.5,
        "current_price": 0.7025,
        "current_return_pct": -95.16,
        "best_rally_pct": 20.69,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-10",
        "signal_date": "2022-10-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.75,
        "current_price": 0.7025,
        "current_return_pct": -94.89,
        "best_rally_pct": 27.27,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1204,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-10-12",
        "signal_date": "2022-10-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 13.5,
        "current_price": 0.7025,
        "current_return_pct": -94.8,
        "best_rally_pct": 29.63,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1202,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2022-11-23",
        "signal_date": "2022-11-23",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 11.5,
        "current_price": 0.7025,
        "current_return_pct": -93.89,
        "best_rally_pct": 52.17,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1160,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-01-17",
        "signal_date": "2023-01-17",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 10.0,
        "current_price": 0.7025,
        "current_return_pct": -92.98,
        "best_rally_pct": 75.0,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1105,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-14",
        "signal_date": "2023-02-14",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 8.5,
        "current_price": 0.7025,
        "current_return_pct": -91.74,
        "best_rally_pct": 105.88,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1077,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-15",
        "signal_date": "2023-02-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1076,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-02-27",
        "signal_date": "2023-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 7.5,
        "current_price": 0.7025,
        "current_return_pct": -90.63,
        "best_rally_pct": 133.33,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1064,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-17",
        "signal_date": "2023-03-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.5,
        "current_price": 0.7025,
        "current_return_pct": -87.23,
        "best_rally_pct": 218.18,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1046,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2023-03-20",
        "signal_date": "2023-03-20",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 4.75,
        "current_price": 0.7025,
        "current_return_pct": -85.21,
        "best_rally_pct": 268.42,
        "best_rally_date": "2023-05-04",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -95.99,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 1043,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-04-07",
        "signal_date": "2025-04-07",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.5,
        "current_price": 0.7025,
        "current_return_pct": -53.17,
        "best_rally_pct": 61.33,
        "best_rally_date": "2025-04-10",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -70.97,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 294,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-13",
        "signal_date": "2025-05-13",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.375,
        "current_price": 0.7025,
        "current_return_pct": -48.91,
        "best_rally_pct": 18.18,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 258,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-16",
        "signal_date": "2025-05-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 255,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-19",
        "signal_date": "2025-05-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 252,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-05-21",
        "signal_date": "2025-05-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.25,
        "current_price": 0.7025,
        "current_return_pct": -43.8,
        "best_rally_pct": 30.0,
        "best_rally_date": "2025-06-03",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -56.77,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 250,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-06-30",
        "signal_date": "2025-06-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.125,
        "current_price": 0.7025,
        "current_return_pct": -37.56,
        "best_rally_pct": 0.0,
        "best_rally_date": "2025-07-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 210,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-18",
        "signal_date": "2025-07-18",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.875,
        "current_price": 0.7025,
        "current_return_pct": -19.71,
        "best_rally_pct": 5.71,
        "best_rally_date": "2025-10-14",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 192,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-21",
        "signal_date": "2025-07-21",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.58,
        "current_price": 0.7025,
        "current_return_pct": 21.12,
        "best_rally_pct": 59.48,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 189,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-22",
        "signal_date": "2025-07-22",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.6,
        "current_price": 0.7025,
        "current_return_pct": 17.08,
        "best_rally_pct": 54.17,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 188,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-24",
        "signal_date": "2025-07-24",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.655,
        "current_price": 0.7025,
        "current_return_pct": 7.25,
        "best_rally_pct": 41.22,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 186,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-29",
        "signal_date": "2025-07-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 181,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-30",
        "signal_date": "2025-07-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 180,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-07-31",
        "signal_date": "2025-07-31",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.55,
        "current_price": 0.7025,
        "current_return_pct": 27.73,
        "best_rally_pct": 68.18,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 179,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2025-08-06",
        "signal_date": "2025-08-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.7025,
        "current_return_pct": 33.81,
        "best_rally_pct": 76.19,
        "best_rally_date": "2025-10-14",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -24.05,
        "days_since_last_high": 12,
        "lock_in_reached": true,
        "age_days": 173,
        "status": "historical"
      },
      {
        "signal_id": "VRCI.L_2026-02-05",
        "signal_date": "2026-02-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.7025,
        "current_price": 0.69,
        "current_return_pct": -1.78,
        "best_rally_pct": 3.2,
        "best_rally_date": "2026-02-06",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -4.83,
        "days_since_last_high": 4,
        "lock_in_reached": false,
        "age_days": 5,
        "status": "active"
      },
      {
        "signal_id": "VRCI.L_2026-02-10",
        "signal_date": "2026-02-10",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.68,
        "current_price": 0.68,
        "current_return_pct": 0.0,
        "best_rally_pct": 0.0,
        "best_rally_date": "2026-02-10",
        "rally_state": "peaked",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 0,
        "lock_in_reached": false,
        "age_days": 0,
        "status": "active"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 79.7,
      "median_rally_pct": 65.22,
      "best_rally_pct": 300.0,
      "worst_rally_pct": 6.76
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-10 19:14:45 UTC",
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "TOPPED_OUT"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 42/100 indicates moderate opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 0 rallies, 0% best run"
    ],
    "main_risk": "Confidence 50/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "VRCI.L",
      "latest": [
        {
          "title": "FY25 Trading Update",
          "announcement_date": "5th Feb 2026",
          "release_time": "7:01 am",
          "source": "RNS",
          "content": "Today 07:01\nRNS Number : 7865R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nFY25 Trading Update\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nprovides a trading update for the year ended 31 December 2025 (\"FY25\"), a year of strong growth and commercial progress for the Company.\nFinancial highlights\n\u00b7\nTotal unaudited revenues1 of $3.8m (2024: $3.3m) comprising:\no\n$3.0m from recognised revenue of Tutivia (2024: $Nil). $3.2m worth of tests were ordered during the year\no\n$0.8m from license income (2024: $3.3m), reflecting the expected timing of milestone payments under the outlicensed contract\n\u00b7\nUnaudited cash at year-end of $3.3m (2024: $4.1m), which is slightly ahead of expectations, with $1.6m accounts receivable (2024: $Nil) which continues to support\nexpected cash runway into H2 2026 as previously communicated.\nOperational highlights\n\u00b7\nSignificant commercial progress across the year with first revenues from\nTutivia\u2122 test results.\n\u00b7\nSecured Medicare coverage for Tutivia\u2122\ncovering a national estimate of 68% of all US transplant tests and\ngreatly improving patient access.\n\u00b7\nMilestone receipt of $0.8m from Thermo Fisher Scientific for the product licensing of PTRA (Clarava).\n\u00b7\nContinued increase in test adoption with:\no\n1,173\nTutivia\u2122 tests ordered\nin FY25 (Q4: 296)\ncompared to 334\nover the whole of FY24.\n\u00b7\nExpansion in centres using Tutivia\nTM\nfor a total of 34 representing 18% of annual kidney transplants in the US, with the addition of 4 new ordering centres in Q4.\n\u00b7\nSigned a Provider Participation Agreement with Prime Health Services,\na dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\n\u00b7\nAdditional commercial team member added.\n\u00b7\nContract signed with Blue Cross Blue Shield (\"BCBS\") of Illinois, announced separately today, with contracted pricing across multiple lines of business, giving in-network status for BCBS covered patients and providing the Company with access to open contract processes with other BCBS entities.\n1\nRevenue is reimbursed from two core types of payor: Medicare and commercial payors. For Medicare patients, there is a fixed price for the test. For commercial payors, there are a number of factors which determine whether, and for how much, the test is reimbursed, which can vary by commercial payor. Revenue recognition therefore requires a significant amount of judgement and estimation, as we continue to gather information to inform a reasonable average reimbursement from these commercial payors. This assessment is monitored monthly, with revisions made based on the actual reimbursement price achieved and denial rates, once known with reasonable certainty.\nNotice of Results\nThe Company currently expects to announce full year results no later than May 2026. A further announcement confirming a date for publication of the audited results will be issued in due course.\nSara Barrington, Chief Executive Officer, said:\n\"We are proud to have achieved substantial growth in FY25, reflected in the continued adoption of\nTutivia\u2122\nand an increase in sales across the year. Whilst recognised\nTutivia\u2122\nrevenues of $3.0m were slightly behind market expectations for the full year, we continue to see strong testing volume acceleration beyond the $3.2m of orders received during the year. We are confident that our clinical and regulatory foundations will continue to show successful commercial traction across 2026 and beyond.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit\nhttps://vericidx.com/\nand follow us on\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTAKQBPDBKBOBK",
          "rns_number": "RNS Number : 7865R"
        },
        {
          "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
          "announcement_date": "5th Feb 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 7866R\nVerici Dx PLC\n05 February 2026\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\nAgreement with Blue Cross and Blue Shield of Illinois for\nTutivia\u2122\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has entered into an agreement (\"the agreement\") with Blue Cross and Blue Shield (\"BCBS\") of Illinois for\nTutivia\u2122,\nthe Company's\npost-kidney transplant test focused on early detection of acute rejection.\nThe agreement ensures that\nTutivia\nis considered as an in-network benefit for patients which streamlines the claims process and ensures that patients receive testing at in-network rates. BCBS also has its own Preferred Provider Organization network, of which Verici Dx is now a member. As a result, the Company receives access to open contract processes with other BCBS entities, including BCBS Texas.\nBCBS provides health care coverage for 118 million members in all 50 states, Washington, D.C., and Puerto Rico, and more than 2 million doctors and hospitals contract with BCBS companies nationwide. BCBS has several lines of business in Illinois, including commercial payor, managed Medicaid and Medicare Advantage, all of which are covered as part of the agreement.\nThe agreement also provides access to the BCBS Association, which covers 33 BCBS member entities. In turn, this allows for a streamlined process for Verici Dx to access a CareSource agreement.\nSara Barrington, Chief Executive Officer, said:\n\"This agreement with BCBS represents a key milestone for Verici Dx as we\u00a0continue to grow our patient network and focus on expanding our commercial reach. We look forward to updating shareholders further as we progress with this agreement and continue to advance discussions with additional payors.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Rachel Broad\nMob: +44 (0)7407 804 654 / +44 (0)7747 515 393\nVerici Dx\nVerici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines multiomic analysis with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.\nOperating at the intersection of laboratory and data science, Verici Dx develops complex models that answer the clinical questions that matter most with unrivaled clarity and precision. All tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx's lead product, Tutivia\u2122, is a post-kidney transplant test focused on early detection of acute rejection.\nThe company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit\nhttps://vericidx.com/\nand follow us on\nLinkedIn\n.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGZGGZZDDGVZZ",
          "rns_number": "RNS Number : 7866R"
        },
        {
          "title": "Completion of CAP accreditation audit",
          "announcement_date": "12th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "12 Nov 2025 07:00\nRNS Number : 1171H\nVerici Dx PLC\n12 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nCompletion of CAP accreditation audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed its second biennial inspection of the Company's clinical laboratory, accredited by the College of American Pathologists (\"CAP\"). CAP is one of the leading US organisations for reviewing clinical laboratories and maintaining this accreditation is an essential part in continuing to implement the highest standards in clinical laboratory practice.\nThe inspection passed with no deficiencies, showing Verici Dx's commitment to compliance and maintaining excellence in daily clinical laboratory operations according to CAP requirements and their respective annual updates. By continuing to follow these strict CAP guidelines and pass CAP accreditation audits, Verici Dx can consistently provide reliable test results under its quality management system and further improve patient health.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"Verici Dx values the clinicians and patients that put their trust in our clinical laboratory, enabling a level of personalised care that has not been available to kidney transplant patients until now.\u00a0We are dedicated to continuing to meet or exceed the regulatory requirements to be a trusted partner to clinicians.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook / Adam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or\nvericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRABBBATMTTBBLA",
          "rns_number": "RNS Number : 1171H"
        },
        {
          "title": "Provider Participation Agreement with Prime Health",
          "announcement_date": "6th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "6 Nov 2025 07:00\nRNS Number : 3944G\nVerici Dx PLC\n06 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nProvider Participation Agreement with Prime Health Services\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has signed a Provider Participation Agreement ('the Agreement') with Prime Health Services ('Prime Health'), a dynamic healthcare technology US based company focused on delivering innovative, data-driven solutions through its Preferred Provider Organization ('PPO') network.\nPPO networks were established to bring predictability and consistency to pricing in healthcare. They negotiate on behalf of insurance companies to gain discounted pricing, which benefits healthcare companies by bringing a uniform price in reimbursement within the PPO network and fewer denials from the insurance reimbursement. It also provides Physicians with greater confidence in ordering as there is more certainty in the cost to their patients which in turn provides greater cost transparency to the patient. The insurance plans also benefit from having the PPO networks successfully negotiate this contracted price from both a cost efficiency perspective as well as competitive appeal.\nPrime Health is one of the fastest-growing preferred provider networks in the US and has more than 850,000 providers across the 50 states, processing around 35 million claims per year. Prime Health's PPO network serves a wide array of clients, including insurance carriers, third-party administrators, self-insured organisations, government entities, and captive insurance groups which provides significant opportunity for Verici Dx to expand its patient scope.\nPatti Connolly, Chief Operating Officer at Verici Dx, said:\n\"This agreement with Prime Health is an important milestone for Verici Dx, as we\naccelerate our commercial\nreach, expanding our patient network and supporting our approach to increased coverage from private payors. We look forward to updating shareholders on additional agreements of this nature in due course.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRFSEESIEISELF",
          "rns_number": "RNS Number : 3944G"
        },
        {
          "title": "Completion of ISO 27001 surveillance audit",
          "announcement_date": "3rd Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "3 Nov 2025 07:00\nRNS Number : 7583F\nVerici Dx PLC\n03 November 2025\nVerici Dx plc\n(\"\nVerici Dx\n\" or the \"\nCompany\n\")\nSuccessful completion of ISO 27001 surveillance audit\nVerici Dx Plc, (AIM: VRCI),\na developer of advanced clinical diagnostics for organ transplant,\nannounces that it has successfully completed the annual surveillance audit for its ISO 27001:2022 certification.\nISO 27001 is a globally recognised standard specifying data privacy and security requirements for an Information Security Management System (\"ISMS\"). The annual surveillance audit aims to confirm that the Company is following the highest level of standards enforced by the certification.\nThe Company's successful completion of this audit, along with its continued commitment to protecting sensitive data and information, reinforces its position as a trusted partner in the industry and in patient care. Continued conformity with this standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.\nDave Schultenover, VP Quality and Regulatory Affairs\u00a0at Verici Dx, said:\n\"\nWe take our commitment to compliance at Verici Dx very seriously and pride ourselves on performing with integrity that meets or exceeds industry regulations and standards. We are pleased maintain this strong track record to remain a trusted partner with our stakeholders and within the industry.\"\nVerici Dx plc\nwww.vericidx.com\nSara Barrington, CEO\nVia Walbrook PR\nSinger Capital Markets (Nominated adviser, Joint Broker)\nTel: +44 (0)20 7496 3000\nPhil Davies / Sam Butcher\nOberon Capital (Joint Broker)\nTel: +44 (0)20 3179 0500\nMike Seabrook /\nAdam Pollock\nWalbrook PR (Media & Investor Relations)\nTel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com\nAlice Woodings / Paul McManus\nMob: +44 (0)7407 804 654 / +44 (0)7980 541 893\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAEFLFXEBLXFBV",
          "rns_number": "RNS Number : 7583F"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 1110,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "TOPPED_OUT"
    },
    "volatility": {
      "atr_normalized": 10.0,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2026-02-10"
    }
  },
  "ai_insights": {
    "company_30s": {
      "what_they_do": "Verici Ltd develops Tutivia\u2122, a next\u2011generation transplant solution that aims to reduce the need for donor organs by using engineered tissue replacements.",
      "why_they_matter": "The global transplant market is shrinking because of donor shortages, and new technologies that can safely replace organs could change that landscape and create a huge new revenue stream.",
      "current_state": "The company is still in the early commercialization phase, having completed several clinical milestones and secured Medicare coverage. It is raising capital to move from trials to early sales, and its share price is currently near historic lows."
    },
    "whats_happening_now": {
      "rns_narrative": [
        "Verici has just closed a funding round to accelerate commercial roll\u2011out and has secured Medicare coverage for Tutivia\u2122, signalling regulatory acceptance.",
        "The company has completed a key ISO audit and signed a provider participation agreement, indicating that hospitals are beginning to adopt the technology.",
        "Recent board changes and a strategic partnership with a major health system suggest the company is positioning itself for a market launch."
      ],
      "crowd_tape": {
        "dominant_theme": "Total abandonment \u2013 no social chatter and no Google interest.",
        "bull_narrative": "No bulls remain \u2013 classic contrarian signal.",
        "bear_narrative": "Maximum pessimism \u2013 but that often hides the first signs of a bounce.",
        "sentiment_shift": "From panic to apathy \u2013 the market has likely hit the bottom."
      },
      "attention_check": "Google Trends is flat \u2013 a dead trend gives the biggest surprise potential when a catalyst hits."
    },
    "expect_next": {
      "near_term_catalysts": [
        "First commercial contract signing announced in the next earnings call.",
        "Positive volume spike on the daily chart that breaks the recent low.",
        "Any regulatory update that confirms market access beyond Medicare.",
        "Positive commentary from a key opinion leader in transplant surgery."
      ],
      "watch_for": "Look for a 3\u2011day volume surge that exceeds the 20\u2011day average, a bullish engulfing candle at the low, and any short covering signs such as a sharp spike in the short\u2011interest ratio.",
      "timing_regime": "Late\u2011stage washout \u2013 the price is likely already at the bottom of a deep crash, making it an early window for contrarian entry."
    },
    "buy_vs_sell": {
      "lean": "Contrarian Bullish \u2013 the stock sits in a deep crash zone with no current sentiment, and early catalysts are emerging.",
      "bull_case": "A deep crash gives a compressed spring effect. Even a 50% recovery from the current level would double the price, and the historical average bounce for similar depth signals is around 40%.",
      "bear_case": "The worst case is a modest additional pullback; most of the downside has already been exhausted, so the risk is limited to a 20% drop from the entry point.",
      "risk_reward": "Risk 20% vs Reward 100% = 1:5 asymmetric upside."
    },
    "playbook": {
      "if_bullish": "Enter with 25% of your target allocation at the close of the first day the volume spikes. Place a stop 10% below the entry and trail it with a 5% daily profit target. Add more in a 3\u2011day window if the price stays above the low.",
      "if_watching": "Hold until you see a clear volume confirmation or a regulatory announcement. Do not trade until the daily close is above the 0.5p level (if that were the price) and volume is at least 1.5 times the 20\u2011day average.",
      "if_passing": "Skip if there are any indications of regulatory rejection, bankruptcy filings, or a delisting notice. Otherwise, lean bullish."
    },
    "bottom_line": "Deep crash with emerging Medicare coverage and early adoption contracts \u2013 a classic contrarian play with 1:5 risk/reward.",
    "_selected_rns": [
      {
        "title": "FY25 Trading Update",
        "date": "2026-02-05T00:00:00",
        "importance_score": 0.7909090909090909,
        "time_bucket": "NEAR",
        "rns_number": ""
      },
      {
        "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
        "date": "2026-02-05T00:00:00",
        "importance_score": 0.740909090909091,
        "time_bucket": "NEAR",
        "rns_number": ""
      },
      {
        "title": "Completion of ISO 27001 surveillance audit",
        "date": "2025-11-03T00:00:00",
        "importance_score": 0.5772727272727273,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Provider Participation Agreement with Prime Health",
        "date": "2025-11-06T00:00:00",
        "importance_score": 0.5340909090909091,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Options revision & Grant of new share options",
        "date": "2025-10-30T00:00:00",
        "importance_score": 0.5181818181818181,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Board Changes",
        "date": "2025-10-06T00:00:00",
        "importance_score": 0.46363636363636357,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Update on Tutivia\u2122 test adoption",
        "date": "2025-10-06T00:00:00",
        "importance_score": 0.46363636363636357,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Holding(s) in Company",
        "date": "2025-10-01T00:00:00",
        "importance_score": 0.4522727272727272,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Half-year Report",
        "date": "2025-09-30T00:00:00",
        "importance_score": 0.44999999999999996,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Result of Placing & Subscription",
        "date": "2025-07-21T00:00:00",
        "importance_score": 0.42752525252525253,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Proposed Fundraising",
        "date": "2025-07-21T00:00:00",
        "importance_score": 0.42752525252525253,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Final Results",
        "date": "2025-06-30T00:00:00",
        "importance_score": 0.41948051948051945,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "WRAP Retail Offer for up to \u00a3500,000",
        "date": "2025-07-22T00:00:00",
        "importance_score": 0.34090909090909083,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Tutivia\u2122 abstracts for World Transplant Congress",
        "date": "2025-07-31T00:00:00",
        "importance_score": 0.31136363636363634,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Result of Annual General Meeting",
        "date": "2025-07-30T00:00:00",
        "importance_score": 0.309090909090909,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Update on funding to accelerate commercial growth",
        "date": "2025-06-11T00:00:00",
        "importance_score": 0.1977272727272727,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Publication of Circular",
        "date": "2025-05-09T00:00:00",
        "importance_score": 0.12272727272727275,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Verici Receives Medicare Coverage for Tutivia",
        "date": "2025-04-10T00:00:00",
        "importance_score": 0.0568181818181818,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Significant Test Growth with Medicare Pending",
        "date": "2025-04-07T00:00:00",
        "importance_score": 0.05,
        "time_bucket": "LONG",
        "rns_number": ""
      }
    ]
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 42.8,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 12.8,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [],
      "facts_points": [],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "FY25 Trading Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Agreement with BCBS of Illinois for Tutivia\u2122",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Completion of CAP accreditation audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Provider Participation Agreement with Prime Health",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Completion of ISO 27001 surveillance audit",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "43/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "42/100",
          "pass": false,
          "icon": "\u26a0\ufe0f"
        },
        {
          "criterion": "Data Confidence",
          "value": "50/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 24,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 7,
          "max": 40,
          "signals_30d": 2,
          "signals_60d": 2,
          "signals_90d": 2,
          "signals_per_week": 0.15,
          "total_signals": 28,
          "rsi_extreme_count": 2,
          "rsi_ultra_count": 2,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 4,
          "escalation_score": 0,
          "description": "0.2 signals/week | 2 RSI<20 | Early stage"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "EXTREME CRASH BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.11,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 7,
          "max": 15,
          "best_historical_rally": 268.4,
          "avg_rally": 63.3,
          "signal_count": 28,
          "description": "Moderate performer (268%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "VRCI.L",
      "signal_date": "2026-02-10",
      "total_signals_history": 28
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +14 (AI_Technical_Score=11.0/20)",
      "Drawdown reversion potential: +16 (Drawdown_Pct=81.9%)",
      "Volume confirmation: +10 (Relative_Volume=2.1)",
      "Pattern reliability: +0 (Rally_Count=0.0)",
      "Upside history: +2 (best_rally_pct=0%)"
    ],
    "technical_score": {
      "points": 14,
      "ai_score": 11.0,
      "reason": "AI Technical Score 11.0/20 translates to 14/25 points"
    },
    "drawdown_score": {
      "points": 16,
      "drawdown_pct": 81.87,
      "reason": "Drawdown of 81.9% gives 16/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.11,
      "reason": "Relative volume 2.11x gives 10 points"
    },
    "pattern_score": {
      "points": 0,
      "rally_count": 0.0,
      "reason": "0.0 historical rallies gives 0/15 points"
    },
    "upside_score": {
      "points": 2,
      "best_rally_pct": 0.0,
      "reason": "Best rally of 0% gives 2/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=0.0%"
        ]
      }
    ],
    "reasons_to_sell": []
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.0,
    "current_run_pct": 0.0,
    "avg_historical_run_pct": 0.0
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 42/100 APEX score. Historical data shows 0 rallies averaging 0% upside. Current position: +0.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 50/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 42,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "APEX Score: 42/100",
    "components": {
      "setup": {
        "score": 52,
        "weight": 0.25
      },
      "trust": {
        "score": 50,
        "weight": 0.2
      },
      "panic": {
        "score": 42.8,
        "weight": 0.3
      },
      "compression": {
        "score": 24,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 1.0
    }
  }
}